Regorafenib-13C-d3
- CAS No.
- 2126178-55-8
- Chemical Name:
- Regorafenib-13C-d3
- Synonyms
- Regorafenib-13C-d3;4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-(methyl-13C-d3)-2-pyridinecarboxamide
- CBNumber:
- CB92675548
- Molecular Formula:
- C21H12ClD3F4N4O3
- Molecular Weight:
- 486.842898134
- MDL Number:
- MFCD28343980
- MOL File:
- 2126178-55-8.mol
Regorafenib-13C-d3 price More Price(3)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Cayman Chemical | 25486 | Regorafenib-13C-d3 ≥99% deuterated forms (d1-d3) | 2126178-55-8 | 500μg | $242 | 2024-03-01 | Buy |
| Cayman Chemical | 25486 | Regorafenib-13C-d3 ≥99% deuterated forms (d1-d3) | 2126178-55-8 | 1mg | $459 | 2024-03-01 | Buy |
| AK Scientific | 0135DY | 4-[4-[[4-Chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-(trideuterio(113C)methyl)pyridine-2-carboxamide | 2126178-55-8 | 1mg | $610 | 2021-12-16 | Buy |
Regorafenib-13C-d3 Chemical Properties,Uses,Production
Description
Regorafenib-13C-d3 is intended for use as an internal standard for the quantification of regorafenib by GC- or LC-MS. Regorafenib is an orally bioavailable multi-kinase inhibitor with anticancer activity.1 It inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRβ with IC50 values of 1.5, 2.5, 4.2, 7, 13, and 22 nM, respectively. Regorafenib also inhibits B-RAF, VEGFR3, FGFR, and Tie2 (IC50s = 28, 46, 202, and 311 nM, respectively) as well as other kinases.1,2,3 In vivo, regorafenib (10 mg/kg) reduces tumor size in the MDA-MB-231 breast and 786-O renal cancer mouse xenograft models.1 It also reduces tumor microvessel area and inhibits tumor growth in a panel of mouse xenograft models. Formulations containing regorafenib have been used in the treatment of advanced gastrointestinal stromal tumors and metastatic colorectal cancer.
References
1. Wilhelm, S.M., Dumas, J., Adnane, L., et al. Regorafenib (BAY 73-
2. Uitdehaag, J.C.M., de Roos, J.A.D.M., van Doornmalen, A.M., et al. Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use PLoS One 9(3),1-13(2014).
3. Ravi, S., and Singal, A.K. Regorafenib: An evidence-
Regorafenib-13C-d3 Preparation Products And Raw materials
Raw materials
Preparation Products
Regorafenib-13C-d3 Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai Hongye Biotechnology Co. Ltd | 400-9205774 | sales@glpbio.cn | China | 6870 | 58 |
| Shenzhen Polymeri Biochemical Technology Co., Ltd. | +86-400-002-6226 13028896684 | sales@rrkchem.com | China | 55896 | 58 |
| QUALITY CONTROL SOLUTIONS LTD. | 13670046396 | ORDERS@QCSRM.COM | China | 18820 | 58 |
| Nanjing Tengyi Biotechnology Co., Ltd | 025-58851786 17714337195 | sales@tybiochem.com | China | 5021 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 8740 | 58 |